Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell ...

A 24-parameter spectral flow cytometry panel was developed to monitor immune receptor expression in MS patients, aiding personalized treatment approaches. The panel detects 12 treatment-associated ...

To insert an in-cell picture saved on your device, from Microsoft's gallery, or imported through the web images search, first ...

Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...

Treatment with Sanofi's frexalimab was seen in a study to safely maintain disease control over 2.5 years in adults with relapsing forms of MS.

In experiments with mouse models of breast, pancreatic, and muscle cancers, researchers at Johns Hopkins All Children's Hospital report new evidence that a novel means of boosting the natural immune ...

A new human liver organoid microarray developed by Cincinnati Children’s and Roche recreates immune-driven liver injury in ...

On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy ...

The drugmaker has launched an international Phase I trial, dubbed Breakfree-2, in seven countries to test the autologous therapy.